Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates

Core Viewpoint - Collegium Pharmaceutical reported quarterly earnings of $1.77 per share, exceeding the Zacks Consensus Estimate of$ 1.54 per share, and showing an increase from $1.58 per share a year ago, representing an earnings surprise of 14.94% [1][2] Financial Performance - The company posted revenues of$ 181.95 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.86%, and up from $149.75 million year-over-year [2] - Over the last four quarters, Collegium has exceeded consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Performance and Outlook - Collegium Pharmaceutical shares have declined approximately 1.1% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's current consensus EPS estimate for the upcoming quarter is$ 1.46 on revenues of $176.91 million, and for the current fiscal year, it is$ 6.53 on revenues of $740.16 million [7] Industry Context - The Medical - Drugs industry, to which Collegium belongs, is currently ranked in the top 50% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Durect, is expected to report a quarterly loss of$ 0.02 per share, with revenues projected to be $6.91 million, reflecting a significant year-over-year increase [9]